FindTrial
Sign In

MEDI3506

DRUG5 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

AsthmaAtopic DermatitisDiabetic Kidney DiseaseHealthy VolunteerPart I (SAD) - Healthy ParticipantsPart II (MAD) - Chronic Obstructive Pulmonary DiseasePart III (J-SD) - Healthy Japanese Participants

Phase 1

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
CompletedNCT03096795
MedImmune LLCPart III (J-SD) - Healthy Japanese Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part I (SAD) - Healthy Participants
Start: 2017-05-15End: 2019-09-30Updated: 2020-10-05
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
CompletedNCT05070312
AstraZenecaHealthy Volunteer
Start: 2021-08-23End: 2022-02-07Updated: 2022-03-25

Phase 2

A Phase 2b Diabetic Kidney Disease Study
CompletedNCT04170543
AstraZenecaDiabetic Kidney Disease
Start: 2019-11-18End: 2023-05-16Updated: 2024-07-10
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
CompletedNCT04212169
AstraZenecaAtopic Dermatitis
Start: 2019-12-09End: 2022-09-20Updated: 2023-09-28
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
CompletedNCT04570657
AstraZenecaAsthma
Start: 2020-09-17End: 2023-02-06Updated: 2024-01-30

Related Papers

Inhibition of IL-33 in Diabetic Kidney Disease
Journal of the American Society of Nephrology2025-12-05
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab (an anti-IL-33 mAb) in early onset asthma
ERJ Open Research2025-09-041 citations
Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program of 1076 Patients
American Journal of Respiratory and Critical Care Medicine2025-05-011 citations
Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (<scp>FRONTIER</scp>‐2)
Journal of the European Academy of Dermatology and Venereology2024-11-136 citations
Abstract 4137311: Inhibition of IL-33 by tozorakimab in patients with diabetic kidney disease: Cardiovascular insights from FRONTIER-1
Circulation2024-11-121 citations
#2267 IL-33 Inhibition with tozorakimab for diabetic kidney disease: a randomized, placebo-controlled phase 2b study
Nephrology Dialysis Transplantation2024-05-011 citations
A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants
Clinical Pharmacology in Drug Development2024-03-251 citations
Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease.
2024-03-189 citations
A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
Clinical Pharmacology & Therapeutics2023-12-2033 citations
#5413 FRONTIER-1: A PHASE 2B STUDY OF IL-33 BLOCKADE IN DIABETIC KIDNEY DISEASE
Nephrology Dialysis Transplantation2023-06-011 citations
Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD
2022-09-04